Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Oxford University has been awarded a £2.4 million grant, as part of the Kennedy Trust MB PhD scheme, to fund undergraduate medical students to undertake DPhil research in the areas of inflammation, immunology and musculoskeletal disease.

The Kennedy Institute of Rheumatology

The scheme will fund 15 students a year for 5 years, 4 of whom will be in Oxford. The other successful Universities Birmingham, Manchester and Glasgow/Edinburgh. The scheme follows the successful launch this year of a BM DPhil educational training program in cancer studies funded by CRUK. Students will be hosted within the Medical Sciences Doctoral training program.

Professor Paul Bowness, Professor of Experimental Rheumatology who led the application, said: "Oxford is thrilled to join the Kennedy Trust MB PhD scheme. This scheme will provide a unique opportunity to educate a new generation of clinician scientists, harnessing Oxford's established research strengths. We are confident these doctors will lead research for the benefit of patients with musculoskeletal diseases many years to come."

The full story is available on the Nuffield Department of Orthopaedics, Rheumatology & Musculoskeletal Sciences website.

Similar stories

Long COVID: vaccination could reduce symptoms, new research suggests

While evidence suggests that people who are vaccinated before they get COVID are less likely to develop long COVID than unvaccinated people, the effectiveness of vaccination on existing long COVID has been less clear.

Com-COV vaccine study to research third dose booster options for 12-to-15-year-olds

Researchers running the University of Oxford-led Com-COV programme have launched a further study of COVID-19 vaccination schedules in young people aged 12 to 15 – with a focus on assessing different options for a third dose booster vaccination.

Population-scale study highlights ongoing risk of COVID-19 in some cancer patients despite vaccination

COVID-19 vaccination is effective in most cancer patients, but the level of protection against COVID-19 infection, hospitalisation and death offered by the vaccine is less than in the general population and vaccine effectiveness wanes more quickly.

New reporting guidelines developed to improve AI in healthcare settings

New reporting guidelines, jointly published in Nature Medicine and the BMJ by Oxford researchers, will ensure that early studies on using Artificial Intelligence (AI) to treat real patients will give researchers the information needed to develop AI systems safely and effectively.

Major boost for Oxford’s mission to counter future pandemic threats

The Moh Family Foundation has given a substantial gift to support the work of Oxford University’s Pandemic Sciences Institute, greatly strengthening its ability to identify and counter future pandemic threats and ensure equitable access to treatments and vaccines around the world.